vs
CytomX Therapeutics, Inc.（CTMX）与Pioneer Bancorp, Inc.（PBFS）财务数据对比。点击上方公司名可切换其他公司
Pioneer Bancorp, Inc.的季度营收约是CytomX Therapeutics, Inc.的1.3倍（$25.0M vs $18.7M），Pioneer Bancorp, Inc.净利率更高（82.1% vs -0.8%，领先82.9%），过去两年Pioneer Bancorp, Inc.的营收复合增速更高（144.9% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
先锋银行控股公司（马里兰州）是一家美国银行控股企业，为先锋银行的母公司，主要面向马里兰州本地社区用户提供零售及商业银行服务，涵盖存款账户、住房与商业抵押贷款、消费贷款及小微企业融资等产品。
CTMX vs PBFS — 直观对比
营收规模更大
PBFS
是对方的1.3倍
$18.7M
净利率更高
PBFS
高出82.9%
-0.8%
两年增速更快
PBFS
近两年复合增速
-15.9%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $25.0M |
| 净利润 | $-154.0K | $3.7M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 21.3% |
| 净利率 | -0.8% | 82.1% |
| 营收同比 | -25.7% | — |
| 净利润同比 | 97.6% | — |
| 每股收益（稀释后） | — | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXPBFS
| Q4 25 | — | $25.0M | ||
| Q3 25 | — | $24.0M | ||
| Q2 25 | $18.7M | $24.4M | ||
| Q1 25 | $50.9M | $22.8M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $33.4M | $22.0M | ||
| Q2 24 | $25.1M | $20.9M | ||
| Q1 24 | $41.5M | $21.6M |
净利润CTMXPBFS
| Q4 25 | — | $3.7M | ||
| Q3 25 | — | $4.3M | ||
| Q2 25 | $-154.0K | $6.5M | ||
| Q1 25 | $23.5M | $5.8M | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $6.3M | ||
| Q2 24 | $-6.5M | $3.9M | ||
| Q1 24 | $13.8M | $4.7M |
营业利润率CTMXPBFS
| Q4 25 | — | 21.3% | ||
| Q3 25 | — | 23.4% | ||
| Q2 25 | -6.9% | 33.3% | ||
| Q1 25 | 44.4% | 32.5% | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | 37.2% | ||
| Q2 24 | -33.7% | 24.1% | ||
| Q1 24 | 28.1% | 28.1% |
净利率CTMXPBFS
| Q4 25 | — | 82.1% | ||
| Q3 25 | — | 18.0% | ||
| Q2 25 | -0.8% | 26.4% | ||
| Q1 25 | 46.2% | 25.3% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | 28.7% | ||
| Q2 24 | -26.0% | 107.4% | ||
| Q1 24 | 33.3% | 21.9% |
每股收益（稀释后）CTMXPBFS
| Q4 25 | — | $0.16 | ||
| Q3 25 | — | $0.18 | ||
| Q2 25 | — | $0.26 | ||
| Q1 25 | — | $0.23 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $0.25 | ||
| Q2 24 | — | $0.15 | ||
| Q1 24 | — | $0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $323.9M |
| 总资产 | $175.1M | $2.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXPBFS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $49.0M | — | ||
| Q1 25 | $47.6M | — | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
股东权益CTMXPBFS
| Q4 25 | — | $323.9M | ||
| Q3 25 | — | $314.2M | ||
| Q2 25 | $119.9M | $314.2M | ||
| Q1 25 | $25.0M | $310.7M | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | $303.8M | ||
| Q2 24 | $-31.2M | $296.5M | ||
| Q1 24 | $-31.7M | $289.0M |
总资产CTMXPBFS
| Q4 25 | — | $2.2B | ||
| Q3 25 | — | $2.2B | ||
| Q2 25 | $175.1M | $2.1B | ||
| Q1 25 | $98.5M | $2.1B | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | $2.0B | ||
| Q2 24 | $159.2M | — | ||
| Q1 24 | $184.7M | $2.0B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $11.1M |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | — |
| 自由现金流率自由现金流/营收 | -84.6% | — |
| 资本支出强度资本支出/营收 | 0.1% | — |
| 现金转化率经营现金流/净利润 | — | 2.97× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | — |
8季度趋势，按日历期对齐
经营现金流CTMXPBFS
| Q4 25 | — | $11.1M | ||
| Q3 25 | — | $3.9M | ||
| Q2 25 | $-15.8M | $5.1M | ||
| Q1 25 | $-21.0M | $-3.5M | ||
| Q4 24 | $-19.9M | — | ||
| Q3 24 | $-20.7M | $1.9M | ||
| Q2 24 | $-19.5M | $9.0M | ||
| Q1 24 | $-26.0M | $3.3M |
自由现金流CTMXPBFS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
自由现金流率CTMXPBFS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
资本支出强度CTMXPBFS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
现金转化率CTMXPBFS
| Q4 25 | — | 2.97× | ||
| Q3 25 | — | 0.90× | ||
| Q2 25 | — | 0.78× | ||
| Q1 25 | -0.89× | -0.61× | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | 0.30× | ||
| Q2 24 | — | 2.30× | ||
| Q1 24 | -1.89× | 0.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
PBFS
暂无分部数据
